Panion & Bf Biotech Inc. (1760.TW)
TWD 68.7
(-2.41%)
TWD 68.7
(-2.41%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 77.21 Million TWD | -57.65% |
| 2022 | 182.34 Million TWD | 74.66% |
| 2021 | 104.4 Million TWD | 274.19% |
| 2020 | 27.9 Million TWD | -82.71% |
| 2019 | 161.32 Million TWD | 1.36% |
| 2018 | 159.17 Million TWD | 75.8% |
| 2017 | 90.53 Million TWD | 0.91% |
| 2016 | 89.72 Million TWD | 22.91% |
| 2015 | 72.99 Million TWD | 51.23% |
| 2014 | 48.26 Million TWD | 165.96% |
| 2013 | 18.14 Million TWD | 144.74% |
| 2012 | -40.56 Million TWD | -11.86% |
| 2011 | -36.26 Million TWD | 7.75% |
| 2010 | -39.3 Million TWD | -872.5% |
| 2009 | 5.08 Million TWD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 20.12 Million TWD | -54.13% |
| 2024 Q1 | 43.86 Million TWD | 48.1% |
| 2023 Q4 | 29.61 Million TWD | 286.52% |
| 2023 FY | 77.21 Million TWD | -57.65% |
| 2023 Q1 | 22.69 Million TWD | 123.55% |
| 2023 Q2 | 17.24 Million TWD | -24.01% |
| 2023 Q3 | 7.66 Million TWD | -55.56% |
| 2022 Q1 | 39.55 Million TWD | 889.95% |
| 2022 Q3 | 77.97 Million TWD | -51.62% |
| 2022 Q4 | -96.35 Million TWD | -223.58% |
| 2022 FY | 182.34 Million TWD | 74.66% |
| 2022 Q2 | 161.17 Million TWD | 307.5% |
| 2021 Q3 | 59.86 Million TWD | -19.45% |
| 2021 Q4 | -5 Million TWD | -108.36% |
| 2021 FY | 104.4 Million TWD | 274.19% |
| 2021 Q1 | -24.78 Million TWD | -165.83% |
| 2021 Q2 | 74.32 Million TWD | 399.87% |
| 2020 Q4 | 37.65 Million TWD | 1407.85% |
| 2020 Q1 | 708 Thousand TWD | -98.76% |
| 2020 Q3 | -2.87 Million TWD | 62.02% |
| 2020 FY | 27.9 Million TWD | -82.71% |
| 2020 Q2 | -7.58 Million TWD | -1170.76% |
| 2019 FY | 161.32 Million TWD | 1.36% |
| 2019 Q4 | 56.96 Million TWD | 211.36% |
| 2019 Q1 | 39.63 Million TWD | -56.84% |
| 2019 Q3 | 18.29 Million TWD | -60.61% |
| 2019 Q2 | 46.43 Million TWD | 17.16% |
| 2018 Q1 | 5.27 Million TWD | -63.01% |
| 2018 FY | 159.17 Million TWD | 75.8% |
| 2018 Q4 | 91.84 Million TWD | 318.33% |
| 2018 Q3 | 21.95 Million TWD | -45.26% |
| 2018 Q2 | 40.1 Million TWD | 661.04% |
| 2017 Q1 | 34.81 Million TWD | -47.39% |
| 2017 Q2 | 15.02 Million TWD | -56.85% |
| 2017 Q3 | 26.44 Million TWD | 76.03% |
| 2017 FY | 90.53 Million TWD | 0.91% |
| 2017 Q4 | 14.24 Million TWD | -46.14% |
| 2016 Q2 | 4.52 Million TWD | 0.0% |
| 2016 Q4 | 66.18 Million TWD | 356.92% |
| 2016 Q3 | 14.48 Million TWD | 220.31% |
| 2016 FY | 89.72 Million TWD | 22.91% |
| 2016 Q1 | 4.52 Million TWD | -85.06% |
| 2015 FY | 72.99 Million TWD | 51.23% |
| 2015 Q4 | 30.27 Million TWD | 0.0% |
| 2015 Q3 | 30.27 Million TWD | 386.74% |
| 2015 Q2 | 6.22 Million TWD | 0.0% |
| 2015 Q1 | 6.22 Million TWD | -62.68% |
| 2014 Q2 | 7.46 Million TWD | 0.0% |
| 2014 FY | 48.26 Million TWD | 165.96% |
| 2014 Q1 | 7.46 Million TWD | -0.77% |
| 2014 Q4 | 16.66 Million TWD | 0.0% |
| 2014 Q3 | 16.66 Million TWD | 123.22% |
| 2013 Q3 | 7.52 Million TWD | 385.64% |
| 2013 Q4 | 7.52 Million TWD | 0.0% |
| 2013 FY | 18.14 Million TWD | 144.74% |
| 2013 Q1 | 1.54 Million TWD | 113.27% |
| 2013 Q2 | 1.54 Million TWD | 0.0% |
| 2012 FY | -40.56 Million TWD | -11.86% |
| 2012 Q3 | -11.67 Million TWD | 0.0% |
| 2012 Q4 | -11.67 Million TWD | 0.0% |
| 2012 Q2 | - TWD | 0.0% |
| 2011 Q4 | - TWD | 0.0% |
| 2011 FY | -36.26 Million TWD | 7.75% |
| 2011 Q2 | - TWD | 0.0% |
| 2010 FY | -39.3 Million TWD | -872.5% |
| 2010 Q4 | - TWD | 0.0% |
| 2009 FY | 5.08 Million TWD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Apex Biotechnology Corp. | 115.78 Million TWD | 33.307% |
| Sinphar Pharmaceutical Co.,Ltd. | 375.17 Million TWD | 79.418% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 264.9 Million TWD | 70.851% |
| GenMont Biotech Incorporation | 32.99 Million TWD | -134.061% |
| Abnova (Taiwan) Corporation | 43.67 Million TWD | -76.792% |
| Adimmune Corporation | -639.89 Million TWD | 112.068% |
| Tanvex BioPharma, Inc. | -2.13 Billion TWD | 103.613% |
| Polaris Group | -1.57 Billion TWD | 104.898% |
| Energenesis Biomedical CO.,LTD. | -260.38 Million TWD | 129.656% |
| UnicoCell Biomed Co., Ltd. | -84.1 Million TWD | 191.809% |
| PELL Bio-Med Technology Co. Ltd. | -398.75 Million TWD | 119.365% |